The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.

A medium which contains a riboflavin derivative is useful for proliferating and culturing pluripotent stem cells such as iPS cells and ES cells, and is free from degradation due to storage as complete medium.

This disclosure is directed to culture media containing a nicotinamide adenine nucleotide (NAD.sup.+) precursor and/or a NAD pathway substrate. This disclosure is also directed to in vitro methods of improving the cell state in an embryo by contacting a mammalian embryo with a culture medium supplemented with a NAD.sup.+ precursor and/or a NAD pathway substrate. The improvements to the cell state may include increasing the presence of an expanded blastocyst, increasing the attachment rate of the embryo, and/or increasing the derivation of embryonic stem cells from the embryo. In certain embodiments, the media and methods use a NAD.sup.+ precursor. A variety of different NAD.sup.+ precursors can be used in the media and methods, including nicotinic acid (NA) and nicotinamide mononucleotide (NMN).

The present invention relates to a method of cryopreserving a mesenchymal stem cell population, the method comprising: cultivating umbilical cord tissue in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum) to provide outgrowth of mesenchymal stem cells present in the amniotic membrane of the umbilical cord; isolating the mesenchymal stem cell population by collecting the outgrown mesenchymal stem cells; and placing the isolated mesenchymal stem cell population in cryopreserved storage. The invention also relates to a cryopreserved mesenchymal stem population of the amniotic membrane of the umbilical cord.

Some embodiments described herein relate to a method of screening candidate therapeutics for gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease, using an ex vivo biopsy high throughput platform. Some embodiments relate to a high-throughput method of screening an ex vivo biopsy for chromatin modifications associated with an gastrointestinal disease. Some embodiments relate to a multi-omic method of screening candidate therapeutics for treatment of gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease.

A cell reprogramming composition and method wherein the composition includes a base molecule, -nicotinamide mononucleotide, trichostatin A and zwitterionic liposomes and wherein the method includes receiving a cell and reprogramming agents, wherein the reprogramming agents comprise Oct-4, Sox 2 and Klf4, to reprogram the cell to an embryonic state.

The present disclosure provides methods of differentiating pluripotent stem cells, including induced pluripotent stem cells, into lineage-specific floor plate midbrain progenitor cells, determined dopaminergic neuronal progenitor cells, committed dopaminergic neuronal progenitor cells and/or dopaminergic neuronal cells. Also provided are compositions of dopaminergic neuronal progenitor cells and uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease, and articles of manufacture and kits for use thereof.

The invention relates to a method of making a culture medium suitable for isolating a mesenchymal stem cell population from the amniotic membrane of the umbilical cord, the method comprising mixing to obtain a final volume of 500 ml culture medium: i. 250 ml of DMEM ii. 118 ml M171 iii. 118 ml DMEM/F12 iv. 12.5 ml Fetal Bovine Serum (FBS) (final concentration of 2.5%).

The invention also relates to a cell culture medium comprising: DMEM in the final concentration of about 55 to 65% (v/v), F12 in a final concentration of about 5 to 15% (v/v), M171 in a final concentration of about 15 to 30% (v/v) and FBS in a final concentration of about 1 to 8% (v/v).

A preparation method of an ionic rare earth leaching agent includes the following steps: (1) domestication microorganisms with rare earth activated mineral powder culture medium to obtain a microbial suspension; (2) amplifying and culturing the microbial suspension and additives to obtain the amplified culture medium; and (3) mixing the modified sesbania gum with the amplified culture medium to obtain the ionic rare earth leaching agent. The activated mineral powder is the active metal-containing mineral powder in nature, which has excellent cation exchange function after activation, and the activated mineral powder and ionic rare earth mineral powder are used as the medium components to domesticate microorganisms, so that microorganisms can survive in the above-mentioned ionic solution and improve the leaching rate of synergistic leaching ionic rare earth.